Form 4: ATOS CFO Granted 578,000 Stock Options

ATOSSA THERAPEUTICS' Chief Financial Officer, Mark James Daniel, was granted 578,000 stock options with an exercise price of $1.03, vesting over four years.

Summary

• Mark James Daniel, Chief Financial Officer of ATOSSA THERAPEUTICS, INC. (ATOS), was granted 578,000 stock options.
• The options have an exercise price of $1.03 per share.
• The grant date for these options was October 14, 2025.
• The options will expire on October 14, 2035.
• Vesting schedule: 25% vests on October 14, 2026, with the remaining 75% vesting in equal quarterly installments over the subsequent three years, contingent on continued service.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally viewed positively as it aligns management's incentives with shareholder interests for long-term value creation. It reflects a commitment to the company's future performance. However, it is a routine compensation disclosure rather than a direct indicator of immediate operational or financial success.

Positives

• The grant of 578,000 stock options to the Chief Financial Officer aligns management's long-term interests with those of shareholders.
• The options have a 10-year expiration period, providing a significant window for potential value realization.

Negatives

• No negative information is typically disclosed in a Form 4 filing, which is a statutory report of an insider transaction.

Risks

• The value of the options is contingent on the future stock performance of ATOSSA THERAPEUTICS, INC.
• The vesting schedule requires continued service, meaning the options could be forfeited if the CFO's employment terminates before full vesting.

Future Outlook

The options are subject to a vesting schedule, with 25% vesting on October 14, 2026, and the remaining 75% vesting in equal quarterly installments over the subsequent three years, contingent on the Chief Financial Officer's continued service. This indicates a long-term incentive structure.

Industry Context

The grant of stock options is a common form of executive compensation in the biotechnology and pharmaceutical industries, aiming to incentivize long-term performance and align executive interests with shareholder value creation. This practice is standard across publicly traded companies, particularly in sectors requiring significant research and development investment and long product development cycles.

Comparison to Industry Standards

• The grant of stock options as a component of executive compensation is a widely accepted practice across industries, including biotechnology.
• The vesting schedule, typically over three to four years, is also standard, designed to retain executives and incentivize sustained performance.
• The exercise price being set at or above the market price on the grant date (implied by $0.00 price of derivative and $1.03 exercise price) is a common structure for incentive stock options.
• Without specific comparable company data on option grants for CFOs at similar-stage biotech firms, a direct quantitative comparison is not feasible from this filing alone.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of the CFO's financial interests with long-term shareholder value.
• Management: The CFO receives a significant long-term incentive, potentially increasing motivation and retention.

Next Steps

• The Chief Financial Officer will continue to serve the Issuer to meet the vesting conditions for the stock options.
• The options will begin vesting on October 14, 2026, with subsequent quarterly vesting installments.
• The Chief Financial Officer may choose to exercise the vested options at any point before their expiration on October 14, 2035, subject to company policy and market conditions.

Key Dates

Keywords

ATOSSA THERAPEUTICS, ATOS, Stock Options, Chief Financial Officer, Mark James Daniel, Insider Transaction, Executive Compensation, Form 4, Equity Grant